share_log

T2 Biosystems | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-JACOB SAFIER(4.3%),NEW DIMENSIONS TRADING LTD.(4.3%)

T2 Biosystems | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-JACOB SAFIER(4.3%),NEW DIMENSIONS TRADING LTD.(4.3%)

T2 Biosystems | SC 13G/A:超過5%持股股東披露文件(修正)-JACOB SAFIER(4.3%),NEW DIMENSIONS TRADING LTD.(4.3%)
美股SEC公告 ·  08/15 20:27

Moomoo AI 已提取核心訊息

On April 12, 2024, T2 Biosystems, Inc., a medical device company, was the subject of a Schedule 13G filing with the United States Securities and Exchange Commission. The filing indicated that New Dimensions Trading Ltd., based in the Cayman Islands, and Jacob Safier, a United States citizen, have reported beneficial ownership of T2 Biosystems' common stock. Both New Dimensions and Safier reported sole voting and dispositive power over 755,000 shares, representing 4.3% of the company's class of securities based on 17,479,954 shares outstanding as reported in T2 Biosystems' Quarterly Statement on Form 10-Q filed on August 8, 2024. The filing, made under Rule 13d-1(c), certifies that the shares were not acquired for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having such purpose or effect. The certification was signed by Chana Edelstein, Director of New Dimensions Trading Ltd., and Jacob Safier on August 15, 2024.
On April 12, 2024, T2 Biosystems, Inc., a medical device company, was the subject of a Schedule 13G filing with the United States Securities and Exchange Commission. The filing indicated that New Dimensions Trading Ltd., based in the Cayman Islands, and Jacob Safier, a United States citizen, have reported beneficial ownership of T2 Biosystems' common stock. Both New Dimensions and Safier reported sole voting and dispositive power over 755,000 shares, representing 4.3% of the company's class of securities based on 17,479,954 shares outstanding as reported in T2 Biosystems' Quarterly Statement on Form 10-Q filed on August 8, 2024. The filing, made under Rule 13d-1(c), certifies that the shares were not acquired for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having such purpose or effect. The certification was signed by Chana Edelstein, Director of New Dimensions Trading Ltd., and Jacob Safier on August 15, 2024.
2024年4月12日,醫療器械公司t2 biosystems成爲美國證券交易委員會提交13G表格的對象。提交顯示總部位於開曼群島的New Dimensions Trading Ltd和美國公民Jacob Safier報告了對T2 Biosystems普通股的受益所有權。New Dimensions和Safier都報告對755,000股擁有單獨的投票和決策權,佔公司未行使的股份類別的4.3%,根據T2 Biosystems提交的Form 10-Q季度報告(於2024年8月8日提交),該公司的未流通股票爲17,479,954股。該提交遵循13d-1(c)規則,證明股份不是爲了更改或影響發行人的控制,也不是與任何具有這種目的或效果的交易有關。提交由New Dimensions Trading Ltd董事Chana Edelstein和Jacob Safier於2024年8月15日簽署。
2024年4月12日,醫療器械公司t2 biosystems成爲美國證券交易委員會提交13G表格的對象。提交顯示總部位於開曼群島的New Dimensions Trading Ltd和美國公民Jacob Safier報告了對T2 Biosystems普通股的受益所有權。New Dimensions和Safier都報告對755,000股擁有單獨的投票和決策權,佔公司未行使的股份類別的4.3%,根據T2 Biosystems提交的Form 10-Q季度報告(於2024年8月8日提交),該公司的未流通股票爲17,479,954股。該提交遵循13d-1(c)規則,證明股份不是爲了更改或影響發行人的控制,也不是與任何具有這種目的或效果的交易有關。提交由New Dimensions Trading Ltd董事Chana Edelstein和Jacob Safier於2024年8月15日簽署。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息